Longeveron’s (LGVN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research note published on Friday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

LGVN has been the topic of several other research reports. Roth Mkm assumed coverage on Longeveron in a research note on Friday, December 6th. They set a “buy” rating and a $10.00 price target on the stock. Roth Capital raised Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th.

Longeveron Stock Up 5.1 %

Shares of LGVN opened at $1.85 on Friday. Longeveron has a 12-month low of $0.77 and a 12-month high of $6.40. The firm has a market capitalization of $27.62 million, a PE ratio of -0.29 and a beta of 0.37. The stock’s fifty day simple moving average is $1.60 and its 200-day simple moving average is $1.84.

Institutional Investors Weigh In On Longeveron

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LGVN. State Street Corp bought a new stake in Longeveron in the third quarter valued at about $29,000. Northern Trust Corp bought a new stake in Longeveron in the fourth quarter valued at about $31,000. Jane Street Group LLC bought a new stake in Longeveron in the fourth quarter valued at about $35,000. Virtu Financial LLC bought a new stake in Longeveron in the fourth quarter valued at about $53,000. Finally, Geode Capital Management LLC increased its holdings in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares during the last quarter. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.